分化型甲状腺癌选择性应用放射性碘治疗的群体队列研究
该回顾性队列纳入1970–2020年手术的3330例分化型甲状腺癌患者,34.9%接受放射性碘治疗,中位随访14.1年10年疾病特异生存率为97.2%。放射性碘整体与疾病特异生存无显著关联,但在转移性患者中与超过80%的风险降低相关。
要点
- 分化型甲状腺癌选择性使用辅助放射性碘治疗可获得极佳疾病特异生存。
- 放射性碘治疗的整体生存获益不显著,最大获益见于转移性患者。
- 转移性分化型甲状腺癌中放射性碘与超过80%的疾病特异死亡风险降低相关。
核心结论
- 分化型甲状腺癌选择性使用辅助放射性碘治疗可获得极佳疾病特异生存,最大获益见于转移性患者。
研究设计与样本
- 基于人群的回顾性队列研究,纳入1970–2020年手术的3330例分化型甲状腺癌患者(783例男性、2547例女性,平均年龄48岁)。
- 采用Kaplan-Meier法估计疾病特异生存与无病生存,log-rank检验评估预后因素,Cox比例风险模型进行多因素分析。
- 使用倾向性评分逆概率治疗加权调整放射性碘组与非放射性碘组预后因素差异,并以竞争风险模型进行二次分析。
主要发现
- 全队列34.9%接受放射性碘治疗(低危24.2%、中危31.1%、高危68.4%),中位随访14.1年,10年疾病特异生存率为97.2%。
- 疾病特异生存受远处转移、切除不完整、高龄、男性、非乳头状组织学及晚期T分期不利影响。
临床怎么用
- 分化型甲状腺癌可选择性使用辅助放射性碘治疗,无需对所有患者常规应用。
- 对转移性分化型甲状腺癌患者,放射性碘治疗与显著降低的疾病特异死亡风险相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over 90% of all thyroid cancers are differentiated thyroid cancer (DTC) with an excellent overall survival rate after thyroidectomy with or without radioactive iodine (RAI) therapy. There is a large variation in the use of RAI therapy in DTC. This population-based study was performed to study the survival advantage offered by RAI therapy in DTC. METHODS: In this population-based retrospective cohort study, we reviewed the medical records of 3330 patients with DTC operated on between 1970 and 2020 and recorded patient and disease characteristics and the oncological status to January 1, 2025. Disease-specific survival (DSS) and disease-free survival (DFS) were estimated by the Kaplan-Meier product limit method, and the association of the individual prognostic factors on DSS and DFS was assessed by the log-rank test. Multivariable analyses were performed with Cox proportional hazards models. Inverse probability of treatment weighting was used to adjust for the difference between the prognostic factors in RAI and non-RAI groups using propensity scores. Secondary analyses were performed using competing risk models to account for the competing influence of non-DTC-related causes of death. RESULTS: Our cohort included 783 males and 2547 females with a mean age of 48 years. RAI therapy was administered to 34.9% of all cases (24.2% of low, 31.1% of intermediate, and 68.4% of high-risk cases, respectively). 10-year DSS was 97.2% after a median follow-up of 14.1 years. DSS was adversely influenced by the presence of distant metastasis, incomplete resection, advanced age, male sex, non-papillary histology, and advanced T stage. RAI therapy was not significantly associated with DSS overall, but it was associated with over 80% risk reduction in metastatic DTC in the Cox proportional hazards model (hazard ratio 0.192; [CI: 0.088-0.417]; p < 0.001) and competing risk analysis (sub-hazard ratio 0.162; [CI: 0.072-0.368]; p < 0.001). CONCLUSIONS: Excellent DSS can be achieved in DTC with selective use of adjuvant RAI, with the greatest benefit of RAI seen in those with metastatic DTC.
引用
- Pathak KA, Agarwal A, Klemm N, et al. Selective Use of Radioiodine Therapy in Differentiated Thyroid Carcinoma: A Population-Based Cohort Study. Thyroid. 2026. PMID: 41817109. doi:10.1177/10507256261416869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。